Klin Onkol 1988; 1(4): 102-104.
Summary: In a group of 98 premeno and postmenopausal patients treated by chemotherapy system CMF vs CMFVP for breast cancer of IIIth clinical stage response rate in 68% of cases has been reached. 2 year survival without any signs of disease in 54% and 5 years survival in 36% of cases with chemotherapy after the chemoinduction and curative radiotherapy. The results are identical regardless of menstrual status and chemotherapy administered. The improvement of 5 years survival by 11% compared with curative radiotherapy only, is significant (p=0,01).
